• About
  • Contact Us
  • Log In

THE MSL

Journal of the MSL Society

  • Current Issue
  • Past Issues
  • How to Submit
  • Search Articles
  • MSL Society
  • Advertise Here

Adaptive Scientific Exchange: Expanding the MSL Toolbox with Agile and Lean Principles

November 4, 2026
Author(s): Azmi A. Ahmad, PhD, Ying Luan, PhD and Dustin M. Dunham, DMSc, DC, MBA, FRSM, FRSPH, FACHDM

Introduction

The modern Medical Science Liaison (MSL) role extends well beyond the dissemination of scientific information, driven by the continuous development of healthcare innovations, expanding scientific complexity, and the growing need to translate evidence into clinical practice [1]. As MSLs transition from purely scientific communicators to strategic intelligence partners, they must develop the ability to rapidly detect emerging trends, unmet needs, shifts in stakeholder perspectives, and evolving healthcare challenges. These skills are necessary for MSLs to successfully predict, navigate, and handle headwinds, identify new opportunities, and effectively drive the adoption of evidence-based principles in clinical practice [2].

Traditional Medical Affairs face several challenges, such as 1) inflexible annual KOL territory plans, 2) slow processes from gathering field insights to organizational response, and 3) difficulty adapting to fast-changing clinical, operational, reimbursement, and competitive environments. Consequently, valuable insights often do not translate into timely learnings or decisions, hindering the ability to meet emerging stakeholders’ needs or adapt to evolving healthcare landscapes.

To create strategic value, Medical Affairs must be flexible and responsive, offering timely intelligence to organizations. As the main link between the organization and external stakeholders, MSLs play a vital role in connecting and speeding up the shift from stakeholder observations to insights, actions, and organizational learning [3,4]. Principles like Agile and Lean, which focus on continuous learning, ongoing improvement, and quick feedback, offer a useful foundation for tackling these challenges. In this context, the LISTEN framework serves as a structured mechanism for stakeholder observation and insight generation, while micro-cycle planning and micro-experiments operationalize these principles through short learning cycles, hypothesis testing, and continuous refinement. Together, the Agile- and Lean-inspired approaches discussed in this article expand the MSL toolbox and enable MSLs to provide real-time, adaptive intelligence, helping pharmaceutical and MedTech organizations respond more efficiently to changing stakeholder needs, clinical updates, and market dynamics.

Deploying Agile and Lean Principles

Agile focuses on small, fast steps, teamwork, and quick changes based on new information [5]. This may include working in sprints and planning medical goals in short, dynamic two-week blocks rather than relying solely on the more static annual KOL territory plans. An emphasis on rapid response enables the development and deployment of quick messaging briefs when new clinical trial results or emerging data are released. Holding reviews immediately after a KOL meeting to assess what worked well (and what didn’t) enables real-time iteration of strategic engagement. Finally, scaling up insights across a field MSL team via daily standups helps the team more quickly identify urgent needs of the broader clinical community.

Where agile principles emphasize team flexibility, iterative cycles, and adapting to evolving stakeholder needs, lean methodology primarily aims to maximize efficiency across entire systems. Lean offers a systematic approach using specific techniques to optimize activities and enhance productivity, efficiency, and effectiveness. Implementing lean successfully requires stakeholder engagement, staff involvement, leadership backing, and a continuous focus on learning and improvement [6,7]. Field-based MSLs can adopt lean principles to function as a coordinated, standardized team rather than as isolated individuals. By prioritizing high-value initiatives, teams can eliminate nonessential activities that waste time and resources. Practical examples include reviewing traditional pre-call planning and travel routines to reduce unnecessary steps, using digital tools for flexible scheduling, aligning KOL scientific exchanges with key insight questions to generate actionable findings, standardizing post-meeting debriefs to capture new insights, and establishing regular feedback loops to keep up with the dynamic clinical landscape.

The LISTEN Framework

Traditionally, MSLs perform background research on KOLs’ scientific interests using a fixed, categorized interaction framework. While essential for initiating contact, the ongoing process of strengthening the relationship is often neglected. Instead of assuming stakeholder preferences are static and unchanging, MSLs can create hypotheses, observe results, and adjust future interactions based on evidence from scientific exchanges. Each interaction becomes an opportunity for MSLs to generate, test, and improve hypotheses about the most effective ways to communicate scientific evidence.

  • Learn the stakeholder’s context, including their expertise, publications, priorities, practice environment, and prior interactions, while treating these assumptions as a working hypothesis rather than a fixed profile
  • Identify a behavioral hypothesis about what may make the exchange more relevant, such as emphasizing outcomes, implementation examples, or collaborative discussions
  • Select one or two specific adaptations, such as adjusting the depth of scientific content, the format of evidence, the pace, or the follow-up approach
  • Test the behavioral hypothesis during the following scientific exchange by evaluating whether the chosen approach improves relevance, clarity, dialogue, understanding, and insight
  • Evaluate engagement signals, scientific insights, and implementation-related observations, such as workflow barriers or evidence gaps
  • Next-step refinement, using lessons learned to refine the hypothesis, optimize the next stakeholder engagement, and inform broader medical education, evidence-generation priorities, resource development, and cross-functional strategy

This approach ensures that scientific exchange is grounded in evidence for its content and guided by evidence in its implementation. The LISTEN Framework aligns conceptually with Plan-Do-Study-Act (PDSA) methods, focusing on iterative testing, learning, and ongoing improvement [8,9].

Accelerating Learning Through Micro-Cycle Planning

To maximize the impact of the LISTEN framework, which operates as iterative cycles of learning and improvement, implementing “micro-cycle planning” with shorter cycle intervals is crucial at both the stakeholder and organizational levels. While traditional industry methods for strategic planning usually involve mid-year reviews and quarterly updates, adopting micro-cycle planning with regular progress and performance check-ins might be better suited to stay reactive-ready.

At the stakeholder level, implementing a structured process like the LISTEN framework to regularly review communication preferences, engagement outcomes, and territory KOL interactions can help MSLs respond more swiftly to unexpected challenges and new opportunities. Organizationally, team leaders can facilitate this through regular micro-cycle reviews, which assess obstacles, spot emerging trends, and allocate resources to support MSL success. By reducing feedback delays between stakeholder insights, analysis, and organizational action, micro-cycle planning connects field observations with cross-functional initiatives, enabling quicker problem-solving, more flexible responses, and prompt translation of insights into evidence-generation, medical education, and strategic planning.

Micro-Experiments in Adaptive Scientific Exchanges

The fundamental idea behind the LISTEN framework and micro-cycle planning is ongoing learning and flexibility. MSLs often adjust their engagement approaches instinctively based on stakeholder interactions and past experiences. Adopting a behavioral experimentation mindset makes these adjustments more intentional, methodical, and reflective. Instead of assuming a stakeholder’s preferences will stay the same over time, the MSL formulates a behavioral hypothesis, tries a small, scientifically grounded change, and monitors its effect on the interaction. Each encounter becomes an opportunity to test ideas, gather insights, and improve future engagement approaches.

A combination of tactics or adaptations may be explored over the course of a stakeholder relationship and, in some cases, within a single engagement. For example, in the early stages of a relationship, discussion may focus on disease mechanisms, emerging evidence, and broad clinical considerations. As the relationship evolves, a KOL may raise specific case examples, implementation challenges that require more tailored discussions, local experience, or detailed follow-ups. The following examples illustrate potential behavioral hypotheses, adaptations, and observations.

Behavioral Hypothesis Adaptation Learning Questions
Stakeholders are more interested in practical implementation than in the mechanism Case-first discussion vs. Mechanism-first discussion
  • Does starting with a clinical or practical case example increase engagement?
  • Does mechanistic depth foster more meaningful scientific dialogue?
  • Which approach yields more implementation-focused questions and follow-up actions?
Stakeholders value contextual relevance and local experience Local data example

vs.

National evidence summary

  • Does local or institutional experience increase engagement and perceived relevance?
  • Is broader evidence preferred as more credible?
  • Which approach generates greater interest in implementation?
Stakeholders prefer concise communication Concise follow-up

vs.

Detailed follow-up

  • Does a concise follow-up increase responsiveness and engagement?
  • Is comprehensive scientific information valued, appreciated, or acted upon?
  • Which approach leads to a more substantive follow-up discussion?
Stakeholders derive greater value from in-person engagement In-person engagement

vs.

Virtual touchpoint

  • Does meeting on-site deepen the relationship?
  • Are strategic or detailed discussions more productive when held in person?
  • Does virtual engagement allow flexibility for more frequent interactions to maintain momentum?
  • What combination of communication channels (e.g., in-person meetings, email follow-up, and site visits) most effectively supports relationship building, documentation of insights and review summary, and better achieves the objectives of the interaction?
Stakeholders are more likely to share candid, actionable insights in focused 1:1 interaction Focused 1:1 discussion

vs.

Advisory/Group meetings

  • Does the stakeholder share more candid or deeper insights during focused 1:1 discussion?
  • Does peer-to-peer interaction stimulate broader discussion, generate ideas, or identify emerging trends?
  • How does the engagement format influence the depth, quality, and actionability of stakeholder insights?

Conclusion

Medical Affairs operates in a fast-changing environment where stakeholders’ needs, clinical evidence, economics, and competition evolve faster than traditional annual planning can keep pace with. The modern MSL must be a timely source of strategic intelligence, constantly listening, learning, and adjusting engagement strategies based on real-time feedback. By implementing agile and lean methods—such as structured scientific exchanges, testing behavioral hypotheses, micro-experiments, and rapid-cycle planning- MSLs can produce actionable insights and quickly spot emerging opportunities and obstacles. Establishing ongoing feedback loops through leadership and company culture will enable MSLs and Medical Affairs teams to deliver more timely, relevant, and impactful medical insights in a rapidly changing healthcare landscape.

Disclosure

Limited artificial intelligence tools were used in the development of this article for searching source material and in language refinement.

References

  1. Grol R, Grimshaw J. From best evidence to best practice: Effective implementation of change in patients’ care. The Lancet. 2003;362(9391):1225-1230. doi:10.1016/S0140-6736(03)14546-1
  2. Setia S, et al. Redefining the role of medical affairs professionals as innovators and leaders in industry-led medical education. Pharm Med. 2024;38(3):167-177. doi:10.1007/s40290-024-00522-1
  3. Friedman CP, Allee NJ, Delaney BC, et al. The science of learning health systems: Foundations for a new journal. Learning Health Systems. 2017;1(1):e10020. doi:10.1002/lrh2.10020
  4. Friedman CP, Rubin JC, Sullivan KJ. Toward an information infrastructure for global health improvement. Yearb Med Inform. 2017;26(01):16-23. doi:10.15265/IY-2017-004
  5. Steegh R, De Voorde KV, Paauwe J, Peeters T. The agile way of working and team adaptive performance: A goal-setting perspective. J Bus Res. 2025;189:115163. doi:10.1016/j.jbusres.2024.115163
  6. Lawal AK, Rotter T, Kinsman L, et al. Lean management in health care: Definition, concepts, methodology and effects reported (systematic review protocol). Syst Rev. 2014;3(1):103. doi:10.1186/2046-4053-3-103
  7. Ellis LD, The importance of adopting a lean mindset and culture for health care organizations, Harvard Medical School, 2020. https://learn.hms.harvard.edu/insights/all-insights/importance-adopting-lean-mindset-and-culture-health-care-organizations
  8. Taylor MJ, McNicholas C, Nicolay C, Darzi A, Bell D, Reed JE. Systematic review of the application of the plan–do–study–act method to improve quality in healthcare. BMJ Qual Saf. 2014;23(4):290-298. doi:10.1136/bmjqs-2013-001862
  9. Bugnitz C, Sandberg KC. Creating effective PDSA cycles. Curr Probl Pediatr Adolesc Health Care. 2025;55(4):101759. doi:10.1016/j.cppeds.2025.101759

About the authors:

Azmi A. Ahmad, PhD

Azmi is a Medical Science Liaison in Cardiology at GE HealthCare with 12+ years of experience in cardiac research across academic and industry work. At GE HealthCare, Azmi supports the advancement of cardiovascular imaging through clinical research, evidence generation, and scientific engagement. With extensive expertise in cardiac PET imaging and development of novel radiotracers, he collaborates with key opinion leaders, academic institutions, and healthcare stakeholders to drive innovation, research initiatives, and clinical adoption.

Ying Luan, PhD

Ying is an Associate Medical Director in Cardiology at GE HealthCare with over 15 years of experience spanning academic research, ultrasound contrast imaging, research and development, and Medical Affairs. She began her industry career as an imaging scientist in GE HealthCare’s Pharmaceutical Diagnostics, R&D organization in the United Kingdom, where she contributed to preclinical research, clinical studies, and cross-functional innovation initiatives focused on advancing contrast-enhanced ultrasound technologies. Following her transition to Medical Affairs in the United States, Ying served as a Medical Science Liaison in Cardiology, where she collaborated with healthcare professionals and key opinion leaders on scientific exchange, medical education, evidence generation, and insight gathering in cardiovascular imaging. In her current role, Ying leads medical strategy and evidence generation initiatives focused on ultrasound contrast imaging, supporting the integration of innovative imaging solutions into clinical practice.

Dustin M. Dunham, DMSc, DC, MBA, FRSM, FRSPH, FACHDM

Dustin is a board-certified clinician and scientist, an executive MBA, and a Medical Affairs strategist with 20+ years of combined pharmaceutical, medical device, and clinical experience. Dustin serves as Head of Global Medical Science for GE HealthCare’s Pharmaceutical Diagnostics organization, serving as the strategic bridge between mid- and late-stage development and commercialization, ensuring that scientific evidence drives business strategy and patient outcomes. Dustin is a Board-Certified Medical Science Liaison, Board-Certified Medical Affairs Specialist, Board-Certified Biologics & Biosimilars Specialist, Board-Certified Patient Advocate, Fellow of the Royal Society of Medicine, Fellow of the Royal Society for Public Health, and Fellow of the American College of Health Data Management.

Have an opinion on this article? Send a message to the editor.

Latest MSL Jobs

See All Jobs

MSL Society Newsletter - Exclusive Insights

Subscribe Now

Copyright © 2026 · The MSL - Journal of the Medical Science Liaison Society